Gyre Therapeutics (GYRE) Invested Capital (2016 - 2025)
Historic Invested Capital for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $137.4 million.
- Gyre Therapeutics' Invested Capital rose 3954.44% to $137.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.4 million, marking a year-over-year increase of 3954.44%. This contributed to the annual value of $98.4 million for FY2024, which is 72169.57% up from last year.
- Per Gyre Therapeutics' latest filing, its Invested Capital stood at $137.4 million for Q3 2025, which was up 3954.44% from $129.4 million recorded in Q2 2025.
- In the past 5 years, Gyre Therapeutics' Invested Capital registered a high of $137.4 million during Q3 2025, and its lowest value of -$28.3 million during Q2 2023.
- Its 5-year average for Invested Capital is $62.2 million, with a median of $79.1 million in 2022.
- Per our database at Business Quant, Gyre Therapeutics' Invested Capital tumbled by 19582.41% in 2023 and then skyrocketed by 269994.31% in 2024.
- Quarter analysis of 5 years shows Gyre Therapeutics' Invested Capital stood at $41.1 million in 2021, then skyrocketed by 75.76% to $72.2 million in 2022, then tumbled by 121.92% to -$15.8 million in 2023, then surged by 721.7% to $98.4 million in 2024, then soared by 39.65% to $137.4 million in 2025.
- Its Invested Capital was $137.4 million in Q3 2025, compared to $129.4 million in Q2 2025 and $104.3 million in Q1 2025.